(Q37601368)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19771491%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

0 references

1 reference

title

A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19771491%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19771491%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Michel Fleith Otuki

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19771491%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Roberto Pontarolo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19771491%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

Astrid Wiens

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19771491%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Cassyano Januário Correr

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19771491%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Mônica Cavichiolo Grochocki

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19771491%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

publication date

22 September 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19771491%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

published in

Clinical Rheumatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19771491%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19771491%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19771491%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

1365-1373

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19771491%20AND%20SRC:MED&resulttype=core&format=json

Pharmacoeconomics of drug therapy for rheumatoid arthritis

8 February 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10067-009-1233-9

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

12 December 2020

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

1 reference

12 December 2020

Muscle strength, pain, and disease activity explain individual subdimensions of the Health Assessment Questionnaire disability index, especially in women with rheumatoid arthritis

1 reference

12 December 2020

Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens

1 reference

12 December 2020

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

12 December 2020

Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis

1 reference

12 December 2020

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

1 reference

12 December 2020

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

1 reference

12 December 2020

Infliximab in active early rheumatoid arthritis

1 reference

12 December 2020

1 reference

12 December 2020

A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis

1 reference

12 December 2020

Assessing heterogeneity in meta-analysis: Q statistic or I2 index?

1 reference

12 December 2020

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity

1 reference

12 December 2020

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

12 December 2020

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

12 December 2020

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

12 December 2020

Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy.

1 reference

12 December 2020

Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis

1 reference

12 December 2020

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

12 December 2020

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

12 December 2020

Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis

1 reference

12 December 2020

Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial

1 reference

12 December 2020

The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial

1 reference

12 December 2020

Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with c

1 reference

12 December 2020

Histological changes in bone marrow after treatment of infliximab for rheumatoid arthritis

1 reference

12 December 2020